Worldwide Biotech/Biopharma Alliance (during Nov. 14 and Nov. 12)
On Nov. 14, 2012, Fujifilm Diosynth Biotechnologies added another licensed product to its list of commercial biopharmaceutical products, following the announcement that ThromboGenics' has received FDA approval for the launch of JETREA? (ocriplasmin) in the USA for the treatment of Symptomatic Vitreomacular Adhesion (VMA).
On Nov. 14, 2012, Sanofi (EURONEXT: SAN and NYSE: SNY) and T1D Exchange, a non-profit organization focused on type 1 diabetes, launched a worldwide study to investigate factors for optimal care for young people with diabetes.
On Nov. 14, 2012, Hainan Haiyao Co. signed a letter of intent to acquire a 40% stake in SinoMab Bioscience Limited.
On Nov. 13, 2012, BaroFold, Inc, a leader in high pressure protein refolding, and Boehringer Ingelheim, a global leader in biopharmaceutical contract development and manufacture, announced a strategic agreement on BaroFold’s Pressure Enabled Manufacturing Technology (PreEMTTM).
On Nov. 13, 2012, Topotarget announced that it has entered into an exclusive license agreement with Oncology Venture ApS granting Oncology Venture global rights to the further clinical development of APO010 as Topotarget continues to focus its operations on the company’s lead candidate belinostat.
On Nov. 13, 2012,TiGenix NV (EURONEXT BRUSSELS: TIG) and pharmaceutical marketing and distribution company Genpharm in Dubai, United Arab Emirates announced signing an exclusive agreement for the commercialization of ChondroCelect? in the Middle East region.
On Nov. 12, 2012, Orchid Chemicals and Pharmaceuticals of India announced it will exit from its ten-year-old JV with North China Pharma, selling its 50% stake to its partner for $13.9 million.
Tags: Alliance/Corporation, Ocriplasmin, Diabetes, PreEMTTM, APO010, ChondroCelect